MEN1 and leukemia: While results of clinical trials testing the safety and efficacy of epigenetic regulators such as specific inhibitors of menin and histone deacetylases for application in KMT2A-r leukemia are awaited, the search for other potent drugs and novel targetable vulnerabilities remains ongoing (2, 23).